Achillion Pharmaceuticals
Oct 17, 2019
EicOsis receives USD 15M to fuel its non-opioid pain therapy; Alexion Pharmaceuticals buys Achillion Pharmaceuticals; Ipsen adds another drug to its rare disease pipeline
EicOsis has received USD 15Million grant from the National Institute of Drug Abuse (NIDA) to fund the clinical trials of non-opioid pain therapy. NIDA, with an aim to supplement NIH’s initiative Helping to End Addiction Long-Term (HEAL Initiative), has awarded the grant to the company. Deaths due to drug ov...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
